Literature DB >> 26333625

Gastrointestinal involvement in Fabry disease. So important, yet often neglected.

J Politei1, B L Thurberg2, E Wallace3, D Warnock3, G Serebrinsky4, C Durand1, A B Schenone1.   

Abstract

Fabry disease is an X-linked metabolic storage disorder due to the deficiency of lysosomal alpha-galactosidase A which causes accumulation of glycosphingolipids, primarily globotriaosylceramide, throughout the body. Gastrointestinal signs and symptoms-abdominal pain, nausea, diarrhea and diverticular disease--are some of the most frequently reported complaints in patients with Fabry disease but are often neglected. Gastrointestinal symptoms are due to intestinal dysmotility as well as impaired autonomic function, vasculopathy and myopathy. Since 2001, enzyme replacement therapy has been a mainstay in treatment of gastrointestinal symptoms of Fabry disease (FD), resulting in reduced gastrointestinal symptoms. Here, we report on four patients with Fabry disease (FD) who manifested early gastrointestinal involvement.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Fabry disease; enzyme replacement therapy; α-galactosidase A

Mesh:

Substances:

Year:  2015        PMID: 26333625     DOI: 10.1111/cge.12673

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  15 in total

1.  Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.

Authors:  William R Wilcox; Ulla Feldt-Rasmussen; Ana Maria Martins; Alberto Ortiz; Roberta M Lemay; Ana Jovanovic; Dominique P Germain; Carmen Varas; Katherine Nicholls; Frank Weidemann; Robert J Hopkin
Journal:  JIMD Rep       Date:  2017-05-17

Review 2.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

Review 3.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

4.  Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.

Authors:  Gustavo Cabrera; Juan Politei; Norberto Antongiovani; Hernán Amartino
Journal:  Mol Genet Metab Rep       Date:  2017-05-04

5.  Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?

Authors:  J Politei; C Durand; A B Schenone; A Torres; J Mukdsi; B L Thurberg
Journal:  Mol Genet Metab Rep       Date:  2017-03-25

6.  Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.

Authors:  Raphael Schiffmann; Daniel G Bichet; Ana Jovanovic; Derralynn A Hughes; Roberto Giugliani; Ulla Feldt-Rasmussen; Suma P Shankar; Laura Barisoni; Robert B Colvin; J Charles Jennette; Fred Holdbrook; Andrew Mulberg; Jeffrey P Castelli; Nina Skuban; Jay A Barth; Kathleen Nicholls
Journal:  Orphanet J Rare Dis       Date:  2018-04-27       Impact factor: 4.123

7.  Autopsy pathology of infantile neurovisceral ASMD (Niemann-Pick Disease type A): Clinicopathologic correlations of a case report.

Authors:  Beth L Thurberg
Journal:  Mol Genet Metab Rep       Date:  2020-07-16

8.  Pathologic substrate of gastropathy in Anderson-Fabry disease.

Authors:  Alessandro Di Toro; Nupoor Narula; Lorenzo Giuliani; Monica Concardi; Alexandra Smirnova; Valentina Favalli; Mario Urtis; Costanza Alvisi; Elena Antoniazzi; Eloisa Arbustini
Journal:  Orphanet J Rare Dis       Date:  2020-06-22       Impact factor: 4.123

Review 9.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06

10.  Fabry Disease With Concomitant Lewy Body Disease.

Authors:  Kelly Del Tredici; Albert C Ludolph; Simone Feldengut; Christian Jacob; Heinz Reichmann; Jürgen R Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2020-04-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.